Immunic (NASDAQ:IMUX) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Immunic (NASDAQ:IMUX - Free Report) in a research report report published on Thursday morning,Benzinga reports. The firm currently has a $10.00 price objective on the stock.

Several other analysts also recently weighed in on the stock. StockNews.com downgraded shares of Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. D. Boral Capital reissued a "buy" rating and set a $17.00 price target on shares of Immunic in a research report on Wednesday, April 30th. B. Riley restated a "buy" rating and set a $6.00 price target on shares of Immunic in a report on Wednesday, April 16th. Finally, William Blair initiated coverage on Immunic in a research note on Tuesday, March 25th. They issued an "outperform" rating on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $13.20.

Immunic Stock Performance

Shares of NASDAQ IMUX traded down $0.03 during midday trading on Thursday, reaching $1.12. 1,114,642 shares of the company's stock were exchanged, compared to its average volume of 696,243. The business's fifty day moving average price is $1.08 and its two-hundred day moving average price is $1.11. The stock has a market capitalization of $107.32 million, a PE ratio of -0.91 and a beta of 1.73. Immunic has a 52-week low of $0.83 and a 52-week high of $2.11.

Institutional Investors Weigh In On Immunic

A number of hedge funds have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in Immunic in the 3rd quarter worth approximately $50,000. Invesco Ltd. bought a new position in shares of Immunic in the fourth quarter worth approximately $37,000. Jane Street Group LLC boosted its stake in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after buying an additional 38,553 shares during the last quarter. HB Wealth Management LLC purchased a new position in shares of Immunic during the 4th quarter valued at about $81,000. Finally, Barclays PLC purchased a new position in shares of Immunic in the fourth quarter valued at about $84,000. Institutional investors own 51.82% of the company's stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.